Month: September 2022

Breaking News

Exclusive: HHS OIG Declines to Penalize Drug Manufacturers at This Time Over 340B Contract Pharmacy Restrictions

In Breaking, Federal, Pharma IndustrySeptember 30, 20222639 Views

The U.S. HHS Office of Inspector General has put off a decision on penalizing drug manufacturers that have placed restrictions on access to 340B discounts in the contract pharmacy setting, 340B Report has learned.

The U.S. Department of Health and Human Services Office of Inspector General (HHS OIG) has informed a bipartisan group of House lawmakers that the enforcement agency does not plan to impose civil monetary penalties against the drug makers

…

Groups Representing 340B Hospitals Praise Federal Court Decision Halting Deep Medicare Part B Cuts

In Federal, Judicial, Pharma Industry, RegulatorySeptember 29, 2022612 Views

Laura Gilcrest and Ted Slafsky

U.S. District Court for the District of Columbia building

The federal district court in Washington, D.C. has ordered the government to immediately begin to pay 340B hospitals at full rates for Medicare Part B covered drugs.

In a big victory for 340B hospitals, a federal judge in Washington, D.C. ruled yesterday that the government must immediately begin to pay 340B hospitals the full Medicare Part B drug payment rate for the remainder of calendar

…

Fallout from New York Times’s 340B Investigative Piece Continues as Local Media, Policymakers, and Community Weighs In

In Federal, Legislative, RegulatorySeptember 29, 2022673 Views

Sarah True and Ted Slafsky

Screenshot of New York Times Bon Secours Mercy Health hospital article

A New York Times investigative story on the 340B program continues to garner attention both locally and nationally.

Shockwaves from the New York Times’ investigative piece on the alleged misuse of 340B savings by a Catholic health system in Richmond, Virginia continues to spread, as local news outlets and government leaders from all levels respond. The

…

Manchin and Braun Call on HHS To Take Immediate Action Against Drug Manufacturers in Contract Pharmacy Battle

In Federal, Legislative, Pharma Industry, RegulatorySeptember 29, 2022379 Views

Laura Gilcrest

Sen. Joseph Manchin (D-WV) and Sen. Michael Braun (R-IN) headshots

Senators Manchin (D-WV) and Braun (R-Ind.) are urging HHS to take action against drug manufacturers who have placed restrictions in the contract pharmacy setting.

Government health officials need to take immediate action to fully enforce the law against drug makers who are denying 340B drug discounts to providers who use contract pharmacies to dispense 340B-priced drugs, U.S. Senator Joe Manchin (D-W.VA.) and

…

CVS Moves to Dismiss New York AG’s Antitrust Suit That Alleges Monopolistic Behavior Related to Wellpartner

In Pharma Industry, StateSeptember 29, 2022246 Views

Laura Gilcrest

CVS has asked a New York state court to dismiss an antitrust lawsuit alleging that the chain is forcing the state’s 340B covered entities to use its 340B third party administrator Wellpartner.

CVS Health Corp. has asked a New York state court to dismiss the state’s antitrust lawsuit alleging that the pharmacy chain is forcing the state’s 340B covered entities to use its 340B third party administrator Wellpartner as a

…

Generic/OTC Drug Maker Owes Refunds to 340B Providers, HRSA Audit Shows

In Federal, Pharma Industry, RegulatorySeptember 29, 2022137 Views

Laura Gilcrest

screenshot of HRSA FY 2022 manufacturer audit results page

HRSA released findings from its audit of drug company VistaPharm.

The U.S. Health Resources Services Administration (HRSA) has ordered South Carolina-based VistaPharm, a manufacturer of generic and over-the-counter (OTC) drugs to repay overcharges to 340B covered entities after a HRSA audit showed the company did not offer its products

…

National Association of Community Health Centers Calls On Congress “To Move Urgently” To Tackle 340B Contract Pharmacy Impasse “Before It’s Too Late”

In Breaking, Federal, Judicial, Legislative, Pharma IndustrySeptember 28, 20221386 Views

Laura Gilcrest and Ted Slafsky

Screenshot of U.S. Dept. of Health and Human Services dispute resolutions document

After the government’s Administrative Dispute Resolution panel dismissed its complaint against drug manufacturers, NACHC is calling for Congress to take urgent action to address the contract pharmacy impasse.

Sparked by the dismissal of its complaint against Astra Zeneca and Sanofi by the government’s Administrative Dispute Resolution Panel (ADR), the National Association of Community Health Centers say “they cannot wait any longer for a solution,” to the

…

New York Times Front Page Story on 340B Program Causes Shockwaves

In Federal, Regulatory, Trade AssociationSeptember 27, 20221617 Views

Laura Gilcrest

screenshot of New York Times article, How a Hospital Chain Used a Poor Neighborhood to Turn Huge Profits

The New York Times weekend front page story on Bon Secours Mercy Health System’s alleged misuse of the 340B program is creating a stir in the 340B community.

340B stakeholders are responding to a long investigative article in Saturday’s New York Times that accuses a Catholic health system of exploiting the 340B discount program at the expense of one of its inner-city hospitals to enrich its

…

340B HIV Providers Warn of “Drug Industry Disinformation Campaign”

In Pharma Industry, Research/Reports, Trade AssociationSeptember 27, 2022304 Views

Sarah True

Drug manufacturers’ true goal is to cripple the 340B program, says Shannon Stephenson, RWC-340B President and CEO of Cempa Community Cares.

Ryan White Clinics for 340B Access (RWC-340B), a national organization of 340B HIV/AIDS medical providers, has published a detailed rebuttal of several recently published articles criticizing the 340B program. RWC-340B accuses article authors—many of whom are supported by

…

PhRMA, BIO, and Others Unleash a Torrent of 340B Hospital Criticism

In Federal, Pharma Industry, Research/Reports, Trade AssociationSeptember 27, 2022282 Views

Tom Mirga and Laura Gilcrest

screenshot of PhRMA blog post September 15, 2022

Headline from recent blog post by PhRMA spokesperson Nicole Longo.

340B disproportionate share hospitals (DSH) in 2020 spent 2.2 times more on outpatient drugs per commercially insured patient than non-340B DSH hospitals and 2.6 times more than other types of 340B hospitals, a new drug industry-funded study shows.

…

Breaking News

Breaking News

Site Footer